U.S. FDA Grants Exemption, EirGenix Terminates Phase III Trial of EG1206A

On the evening of the 24th, EirGenix announced that after consulting with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), the company received positive feedback on requesting an exemption for the Phase III clinical trial of its investigational product EG1206A. As a result, EirGenix has decided to terminate the Phase III trial, potentially allowing the product to reach the market earlier.